Synlogic achieves research milestone in collaboration with roche for development of novel synthetic biotic to treat inflammatory bowel disease

Cambridge, mass., sept. 06, 2022 (globe newswire) -- synlogic, inc. (nasdaq: sybx), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today that it has received a milestone payment for the achievement of prespecified success criteria under the research collaboration agreement with roche for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (ibd).
SYBX Ratings Summary
SYBX Quant Ranking